VBI Vaccines Announces Presentation of Physician-Initiated Compassionate Use Data of its 3-Antigen Hepatitis B Vaccine at the 2022 International HBV Meeting
September 21 2022 - 8:00AM
Business Wire
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical
company driven by immunology in the pursuit of powerful prevention
and treatment of disease, today announced that data from the
physician-initiated compassionate use of VBI’s 3-antigen hepatitis
B vaccine in four adults chronically infected with hepatitis B
virus (HBV) were presented in a poster session at the 2022
International HBV Meeting in Paris, France, on September 19.
Poster Presentation Details
- Title: Therapeutic vaccination of chronically HBV
infected patients with low-level of HBsAg using a combination of a
third generation PreS/S vaccine (Sci-B-Vac™) and a nucleoside
analogue
- Session: Poster Session I
- Date: Monday, September 19, 2022
- Presenter: Hedwig Roggendorf, M.D., Institute of
Molecular Immunology and Experimental Oncology, University Hospital
Rechts der Isar, Technical University of Munich
- Event Website: https://www.hbvmeeting.org/
The poster is archived on the Posters page in the News &
Resources of VBI’s website, here.
About Hepatitis B
Hepatitis B is one of the world’s most significant infectious
disease threats with more than 290 million people infected
globally. HBV infection is the leading cause of liver disease and,
with current treatments, it is very difficult to cure, with many
patients going on to develop liver cancers. An estimated 900,000
people die each year from complications of chronic HBV such as
liver decompensation, cirrhosis, and hepatocellular carcinoma.
About VBI’s 3-Antigen Hepatitis B Vaccine
VBI’s vaccine is the only 3-antigen hepatitis B vaccine,
comprised of the three hepatitis B surface antigens of the
hepatitis B virus – S, pre-S1, and pre-S2. It is approved for use
in the United States, the European Union/European Economic Area,
the United Kingdom, and Israel.
About VBI Vaccines Inc.
VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven
by immunology in the pursuit of powerful prevention and treatment
of disease. Through its innovative approach to virus-like particles
(“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform
technology, VBI develops vaccine candidates that mimic the natural
presentation of viruses, designed to elicit the innate power of the
human immune system. VBI is committed to targeting and overcoming
significant infectious diseases, including hepatitis B,
coronaviruses, and cytomegalovirus (CMV), as well as aggressive
cancers including glioblastoma (GBM). VBI is headquartered in
Cambridge, Massachusetts, with research operations in Ottawa,
Canada, and a research and manufacturing site in Rehovot,
Israel.
For more information, visit www.vbivaccines.com.
Cautionary Statement on Forward-looking Information
Certain statements in this press release that are
forward-looking and not statements of historical fact are
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995
and are forward-looking information within the meaning of Canadian
securities laws (collectively, “forward-looking statements”). The
Company cautions that such statements involve risks and
uncertainties that may materially affect the Company’s results of
operations. Such forward-looking statements are based on the
beliefs of management as well as assumptions made by and
information currently available to management. Actual results could
differ materially from those contemplated by the forward-looking
statements as a result of certain factors, including but not
limited to, the impact of general economic, industry or political
conditions in the United States or internationally; the impact of
the ongoing COVID-19 pandemic on our clinical studies,
manufacturing, business plan, and the global economy; the ability
to successfully manufacture and commercialize PreHevbrio/PreHevbri;
the ability to establish that potential products are efficacious or
safe in preclinical or clinical trials; the ability to establish or
maintain collaborations on the development of pipeline candidates
and the commercialization of PreHevbrio/PreHevbri; the ability to
obtain appropriate or necessary regulatory approvals to market
potential products; the ability to obtain future funding for
developmental products and working capital and to obtain such
funding on commercially reasonable terms; the Company’s ability to
manufacture product candidates on a commercial scale or in
collaborations with third parties; changes in the size and nature
of competitors; the ability to retain key executives and
scientists; and the ability to secure and enforce legal rights
related to the Company’s products. A discussion of these and other
factors, including risks and uncertainties with respect to the
Company, is set forth in the Company’s filings with the SEC and the
Canadian securities authorities, including its Annual Report on
Form 10-K filed with the SEC on March 7, 2022, and filed with the
Canadian security authorities at sedar.com on March 7, 2022, as may
be supplemented or amended by the Company’s Quarterly Reports on
Form 10-Q. Given these risks, uncertainties and factors, you are
cautioned not to place undue reliance on such forward-looking
statements, which are qualified in their entirety by this
cautionary statement. All such forward-looking statements made
herein are based on our current expectations and we undertake no
duty or obligation to update or revise any forward-looking
statements for any reason, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220921005284/en/
VBI Contact Nicole Anderson Director, Corporate
Communications & IR Phone: (617) 830-3031 x124 Email:
IR@vbivaccines.com
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Mar 2024 to Apr 2024
VBI Vaccines (NASDAQ:VBIV)
Historical Stock Chart
From Apr 2023 to Apr 2024